NewAmsterdam Pharma
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-33
RECRUITING3
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| VERMEER NCT06982508 |
P2 | Recruiting | Antioxidant Absorption | 100 | 2026-09 (+5 mo) |
| PREVAIL NCT05202509 |
P3 | Active, not recruiting | Atherosclerotic Cardiovascular Disease | 9541 | 2026-11 |
| VINCENT NCT06496243 |
P2 | Recruiting | Dyslipidemias | 69 | 2026-11 (+20 mo) |
| REMBRANDT NCT06305559 |
P3 | Active, not recruiting | Lipidemia; Coronary Artery Disease | 300 | 2027-11 (+11 mo) |
| RUBENS NCT07219602 |
P3 | Active, not recruiting | Lipidemia; Type 2 Diabetes (T2DM) | 300 | 2028-03 |
| SPINOZA NCT07794670 |
P2 | Recruiting | Preclinical Alzheimer's Disease | 400 | 2028-09 |